Icahn School of Medicine at Mount Sinai, New York, USA.
Department of Internal Medicine, Mount Sinai Morningside/West, New York, USA.
J Pediatric Infect Dis Soc. 2024 Nov 21;13(Supplement_5):S171-S178. doi: 10.1093/jpids/piae070.
The rising prevalence of hepatitis C infections among individuals of reproductive age further emphasizes the importance of evidence-based management of hepatitis C virus (HCV) during pregnancy to minimize perinatal transmission and to optimize maternal and fetal outcomes. In this review, we discuss the most recent recommendations on the management of HCV in pregnancy, including recommendations for screening and treatment during pregnancy and the postpartum period, as well as infant management to reduce perinatal transmission of HCV.
Current guidelines recommend universal HCV screening during each pregnancy. With varying guidance regarding the use of direct-acting antivirals (DAAs) during pregnancy, recent studies have focused on the safety and efficacy of DAA initiation during pregnancy. Additionally, there has been an increased focus on improving treatment rates in the postpartum period through innovative linkage to care efforts, telemedicine, and additional efforts reducing barriers to care for patients.
生殖年龄段人群中丙型肝炎感染的发病率不断上升，这进一步强调了在妊娠期间对丙型肝炎病毒 (HCV) 进行循证管理的重要性，以最大限度地减少围产期传播，并优化母婴结局。在这篇综述中，我们讨论了关于妊娠期间 HCV 管理的最新建议，包括妊娠期间和产后筛查和治疗的建议，以及婴儿管理以降低 HCV 的围产期传播。
目前的指南建议在每次妊娠期间进行 HCV 普遍筛查。由于目前关于在妊娠期间使用直接作用抗病毒药物 (DAA) 的指南存在差异，最近的研究重点是 DAA 在妊娠期间起始的安全性和有效性。此外，还通过创新的护理衔接工作、远程医疗和减少患者护理障碍的额外努力，更加关注提高产后期间的治疗率。
